Literature DB >> 26568317

Gastro-esophageal reflux and antisecretory drugs use among patients with chronic autoimmune atrophic gastritis: a study with pH-impedance monitoring.

A Tenca1, S Massironi1, D Pugliese1, D Consonni2, A Mauro1, F Cavalcoli1, M Franchina1, M Spampatti1, D Conte1, R Penagini1.   

Abstract

BACKGROUND: Patients with chronic autoimmune atrophic gastritis (CAAG) often refer digestive symptoms and are prescribed antisecretory medications. Aims were to investigate: (i) gastro-esophageal reflux (GER), (ii) psychopathological profile, (iii) frequency of use and clinical benefit of antisecretory drugs.
METHODS: Prospective observational study on 41 CAAG patients who underwent: 24 h multichannel intra-luminal impedance-pH (MII-pH) monitoring off-therapy, standardized medical interview and psychological questionnaire (i.e., SCL-90R). The medical interview was repeated at least 1 month after MII-pH in patients who were using antisecretory drugs. Statistical analysis was performed calculating median (10th-90th percentiles) and risk ratios (RR) with 95% confidence interval. KEY
RESULTS: Median intra-gastric pH was 6.2 (4.6-7.0). One patient had acid reflux (AC) associated with symptoms, five had increased total reflux number and four had symptoms associated to non-acid reflux (NA) (patients referred as 'GER positive'). Using patients 'GER negative' with normal SCL-90R as reference, the RR of being symptomatic in patients GER positive was 2.1 (1.1-4.1) if SCL-90R was normal and 0.9 (0.5-1.7) if it was altered (difference in RR significant being p = 0.04). Seventeen/28 (61%) symptomatic patients were on antisecretory drugs, which were stopped in 16 of them according to results of MII-pH and clinical evaluation after 574 days (48-796) showed that symptoms were unchanged. CONCLUSIONS & INFERENCES: In patients with CAAG (i) AC reflux rarely occurred whereas increased NA reflux was not infrequent both being related to symptoms in some patients, (ii) psychopathological profile has a role in symptoms' occurrence, (iii) antisecretory drugs were generally inappropriately used and clinically ineffective.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  acid-related disorder; autoimmune disease; functional disease

Mesh:

Substances:

Year:  2015        PMID: 26568317     DOI: 10.1111/nmo.12723

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

1.  A case of Barrett's oesophagus in pernicious anaemia: acid is not the only culprit!

Authors:  Marilia Carabotti; Edith Lahner; Carola Severi; Bruno Annibale
Journal:  Therap Adv Gastroenterol       Date:  2016-03-14       Impact factor: 4.409

Review 2.  Management of upper gastrointestinal symptoms in patients with autoimmune gastritis.

Authors:  Juan D Gomez Cifuentes; Jordan Sparkman; David Y Graham
Journal:  Curr Opin Gastroenterol       Date:  2022-09-09       Impact factor: 2.741

3.  Symptomatic Non-acidic Reflux in a Patient With Chronic Autoimmune Atrophic Gastritis Successfully Treated With Anti-reflux Surgery.

Authors:  Carlos Teruel; María Jesús de Higes; Patricia Luengo; Eduardo Lobo
Journal:  J Neurogastroenterol Motil       Date:  2018-01-30       Impact factor: 4.924

4.  Upper gastrointestinal symptoms in autoimmune gastritis: A cross-sectional study.

Authors:  Marilia Carabotti; Edith Lahner; Gianluca Esposito; Maria Carlotta Sacchi; Carola Severi; Bruno Annibale
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 5.  Clinical manifestations of chronic atrophic gastritis.

Authors:  Kryssia Isabel Rodriguez-Castro; Marilisa Franceschi; Antonino Noto; Chiara Miraglia; Antonio Nouvenne; Gioacchino Leandro; Tiziana Meschi; Gian Luigi De' Angelis; Francesco Di Mario
Journal:  Acta Biomed       Date:  2018-12-17

Review 6.  Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management.

Authors:  Sheila D Rustgi; Priyesha Bijlani; Shailja C Shah
Journal:  Therap Adv Gastroenterol       Date:  2021-08-31       Impact factor: 4.409

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.